AngioDynamics, Inc.
ANGO Healthcare Medical Instruments & Supplies
AngioDynamics, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $320.2 million, up 9.46% from fiscal 2025. In the quarter to August 2026, revenue grew 6.87%, EPS grew 35.0% and free cash flow grew 5.62%, each against the same quarter a year earlier.
Follow ANGO
AngioDynamics, Inc. (ANGO) EV/Sales
As of 16 October 2026, AngioDynamics, Inc. (ANGO) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from 0.6× (March 2024) to 5.0× (April 2019); the current reading is higher than 29% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.4× | 4.95% |
| FY2025 | 1.4× | 74.88% |
| FY2024 | 0.8× | (32.23%) |
| FY2023 | 1.1× | (53.15%) |
| FY2022 | 2.4× | (19.53%) |
| FY2021 | 3.0× | 106.35% |
| FY2020 | 1.5× | (34.84%) |
| FY2019 | 2.2× | (26.07%) |
| FY2018 | 3.0× | 36.83% |
| FY2017 | 2.2× | 51.04% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2026 | 2.1× | 51.42% |
| May 2026 | 1.4× | (9.13%) |
| Feb 2026 | 1.6× | (13.13%) |
| Nov 2025 | 1.8× | 20.91% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNNN Anbio Biotechnology compare | n/m |
| ZJYL Jin Medical International Ltd. compare | n/m |
| OSUR OraSure Technologies, Inc. compare | 0.8× |
| ANGO AngioDynamics, Inc. | 1.5× |
| EMBC Embecta Corp. compare | 1.6× |
| STAA STAAR Surgical Company compare | 2.7× |
| SMTI Sanara MedTech Inc. compare | 2.9× |
| UTMD Utah Medical Products, Inc. compare | 4.2× |
| AVR Anteris Technologies Global Corp. compare | 148× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)